Collaboration Agreement (Tables)

6 Months Ended

Jun. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Collaboration Revenue

(b) Collaboration Revenue

Collaboration revenue was as follows:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2016		2015		2016		2015
Collaboration revenue:
Related to U.S. XTANDI net sales	$	165,129	$	149,220	$	318,922	$	261,230
Related to ex-U.S. XTANDI net sales		41,036		25,591		69,740		41,358
Related to upfront and milestone payments		—		846		—		2,257
Total	$	206,165	$	175,657	$	388,662	$	304,845

Schedule of Collaboration Revenue Related to U.S. XTANDI Net Sales

Collaboration revenue related to U.S. XTANDI net sales was as follows:

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2016			2015			2016			2015
U.S. XTANDI net sales (as reported by Astellas)	$	330,257		$	298,440		$	637,843		$	522,460
Shared U.S. development and commercialization costs		(95,055	)		(84,947	)		(225,639	)		(195,260	)
Pre-tax U.S. profit	$	235,202		$	213,493		$	412,204		$	327,200
Medivation’s share of pre-tax U.S. profit	$	117,601		$	106,747		$	206,102		$	163,600
Reimbursement of Medivation’s share of shared U.S. costs		47,528			42,473			112,820			97,630
Collaboration revenue related to U.S. XTANDI net sales	$	165,129		$	149,220		$	318,922		$	261,230